Company Description
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors.
The company’s proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer.
It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer.
The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.
| Country | United States |
| Founded | 2007 |
| IPO Date | Oct 29, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 113 |
| CEO | Natalie Holles |
Contact Details
Address: 80 Guest Street, 5th Floor Boston, Massachusetts 02135 United States | |
| Phone | 617 500 8864 |
| Website | aurabiosciences.com |
Stock Details
| Ticker Symbol | AURA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $14.00 |
| CIK Code | 1501796 |
| CUSIP Number | 05153U107 |
| ISIN Number | US05153U1079 |
| Employer ID | 32-0271970 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Natalie C. Holles | President, Chief Executive Officer and Director |
| Anthony S. Gibney | Chief Financial and Business Officer |
| Dr. Jill J. Hopkins M.D. | Chief Medical Officer and President of Research and Development |
| Amy Elazzouzi | Interim Principal Accounting Officer, Senior Vice President of Finance and Treasurer |
| Dr. Mark Plavsic D.V.M., Ph.D. | Chief Technology Officer |
| Conor Kilroy | Chief Legal Officer and Secretary |
| Patrick Nealon | Senior Vice President of Clinical Development Operations |
| Dr. Anthony Daniels M.D. | Vice President and Therapeutic Area of Head Ocular Oncology |
| Joe McQuaid M.D. | Vice President and Therapeutic Area Head of Urologic Oncology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 19, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 12, 2026 | SCHEDULE 13G | Filing |
| May 11, 2026 | 10-Q | Quarterly Report |
| May 11, 2026 | SCHEDULE 13D/A | Filing |
| May 11, 2026 | 8-K | Current Report |
| May 5, 2026 | 8-K | Current Report |
| May 5, 2026 | 424B5 | Filing |
| May 4, 2026 | 8-K | Current Report |
| May 4, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 4, 2026 | S-3MEF | Filing |